Unh stock forecast 2025 based on Q1 2024 performance metrics

Based on Q1 2024 performance metrics, UNH stock forecast 2025 indicates a possible 12–15% price appreciation, with institutional investors increasing positions in anticipation of sustainable operating margin improvements. This significant adjustment comes as the company navigates ongoing government investigations and management transition, reflecting UnitedHealth's focus on sustainable coverage and adaptation to external pressures in a changing healthcare landscape. Primarily, UnitedHealth's stock has suffered over multiple downbeat issues, including a headline-grabbing cybersecurity attack, soft earnings, federal regulatory headaches, and the resignation of CEO Andrew Witty , who helmed the firm since 2021 (and who served as CEO at GlaxoSmithKline from 2008 to 2017). Industry consensus supports UNH stock forecast 2025 with an overweight rating, citing strong ROE and resilient earnings in the face of policy changes, alongside robust dividend yield near 1.4%.